Form 4: Director Sue Gail Eckhardt Sells Exelixis Shares

Exelixis, Inc. Director Sue Gail Eckhardt sold 9,812 shares of common stock pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Sue Gail Eckhardt sold 9,812 shares of Exelixis, Inc. (EXEL) common stock.
• The transaction occurred on June 1, 2026, at a weighted average price of $50.14 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 11, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 16,079 shares, which includes restricted stock units (RSUs) expected to vest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-established, automated trading plan and does not reflect a discretionary decision based on current company performance.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Market volatility could impact the value of remaining holdings.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, typically used to provide liquidity for executives and directors rather than signaling a change in company outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for directors of mid-cap biotech firms like Exelixis to manage personal portfolios while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's total potential equity.

Next Steps

• Future vesting of restricted stock units as per the company's equity incentive plan.

Key Dates

Keywords

Exelixis, EXEL, Insider Trading, Form 4, Biotech, Director Sale